Woodline Partners LP Ionis Pharmaceuticals Inc Transaction History

Woodline Partners LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$38.5 - $47.13 $28 Million - $34.3 Million	-726,838 Reduced 69.76%	315,094 $14.3 Million
Q2 2023 Aug 14, 2023	BUY	$34.73 - $43.33 $36.2 Million - $45.1 Million	1,041,932 New	1,041,932 $42.8 Million
Q3 2022 Nov 14, 2022	BUY	$36.54 - $48.66 $10.1 Million - $13.5 Million	276,575 Added 212.9%	406,483 $18 Million
Q2 2022 Aug 15, 2022	SELL	$31.71 - $43.0 $1.99 Million - $2.7 Million	-62,743 Reduced 32.57%	129,908 $4.81 Million
Q1 2022 May 16, 2022	SELL	$29.88 - $37.04 $6.54 Million - $8.1 Million	-218,803 Reduced 53.18%	192,651 $7.14 Million
Q4 2021 Feb 14, 2022	BUY	$25.61 - $35.1 $153,480 - $210,354	5,993 Added 1.48%	411,454 $12.5 Million
Q3 2021 Nov 15, 2021	SELL	$33.54 - $40.55 $18.7 Million - $22.6 Million	-558,327 Reduced 57.93%	405,461 $13.6 Million
Q2 2021 Aug 16, 2021	BUY	$34.54 - $47.25 $16.9 Million - $23.1 Million	487,897 Added 102.52%	963,788 $38.4 Million
Q1 2021 May 17, 2021	BUY	$42.51 - $63.78 $6.14 Million - $9.22 Million	144,514 Added 43.61%	475,891 $21.4 Million
Q4 2020 Feb 16, 2021	BUY	$45.3 - $60.27 $15 Million - $20 Million	331,377 New	331,377 $18.7 Million

403

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.35B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.